MedTrace Logo

Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.

NCT05483725 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2024-03-06

No results posted yet for this study

Summary

Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in kidney transplant recipients at least one year from transplantation.

Conditions

  • Kidney Diseases
  • Kidney Transplant; Complications
  • COVID-19
  • Vaccine Adverse Reaction
  • Rejection Acute Renal
  • Rejection Chronic Renal

Interventions

BIOLOGICAL

Booster dose of mRNA vaccine

Administration of SARS-CoV-2 mRNA vaccine.

Sponsors & Collaborators

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Principal Investigators

  • Ondrej Viklicky, MD, PhD · Head of Department of Nephrology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2024-12-04
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05483725 on ClinicalTrials.gov